LIPI · Limited-stage IPI

Prognostic index for PET-staged stage I–II diffuse large B-cell lymphoma treated with rituximab-chemotherapy ± radiotherapy.

LIPI score
—
Complete all fields

Patient variables

years
Enter an age between 16 and 120.
÷
Both LDH and the lab upper limit of normal must be greater than 0.
Enter a plausible haemoglobin value (30–250 g/L).

Survival by risk group

Number at risk
Risk group0 y5 y10 y15 y

Show working
TermContribution
Complete the fields above.
Risk groups & thresholds
Risk groupScore5-yr PFS

Whole-cohort outcomes (n=1054, median follow-up 58 months): 5-year PFS 82%, 5-year OS 86%. Five-year OS was reported separately for the high-risk group only (48%).

About this score

The Limited-stage IPI (LIPI) was developed on 1054 adults with newly diagnosed, PET-determined stage I–II DLBCL treated with rituximab-chemotherapy ± radiotherapy across Australian, UK, Canadian and US sites (2013–2019), using a Cox proportional-hazards model under repeated cross-validation (training n=845, validation n=209).

LIPI outperformed the historical stage-modified IPI in both the training cohort (Harrell's C 0.69 vs 0.60) and the validation cohort (0.64 vs 0.59), with risk-group separation preserved on validation.

The score is the linear predictor of the Cox model. It has no units and is interpreted only through the risk-group thresholds above.

For use by qualified clinicians only. This calculator reproduces a published prognostic model and is intended to support, not replace, clinical judgement. It gives a risk-group estimate derived from a population, not a prediction for an individual patient, and must not be used as the sole basis for any treatment decision.